MedTrace Logo

Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome

NCT02295176 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2015-10-27

No results posted yet for this study

Summary

Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity in patients with MetS and increased LV mass.

168 patients will be enrolled in this randomized, double-blind, parallel-group, placebo-controlled trial and treated for 24 weeks.

Conditions

  • Metabolic Syndrome
  • Insulin-resistance
  • Left Ventricular Hypertrophy

Interventions

DIETARY_SUPPLEMENT

Armolipid Plus

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Rottapharm

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-03-31
Completion
2015-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02295176 on ClinicalTrials.gov